Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06228456 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

StatusRecruiting
PhasePhase 4
Started2024-04-01
View on ClinicalTrials.gov ↗

Amendment history

2026-02-03
Study Status v5
Primary completion date2025-12-31→2026-12-31
Completion date2026-04-30→2027-04-30
2025-04-22
Study Status v4
Primary completion date2025-10-31→2025-12-31
Completion date2026-02-28→2026-04-30
2024-04-22
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-05-01→confirmed 2024-04-01
Study sitesdetails revised at 1 of 1 site
2024-03-28
Study Status v2
Start date2024-03-01→2024-05-01
2024-01-30
Study Status v1
Re-verified, no change to tracked fields
2024-01-19
Original filing
The proposed study aims to assess the antiplatelet effects of more potent oral P2Y12 inhibition with low-dose ticagrelor (60 mg bid) compared with standard of care clopidogrel in patients with a high ABCD-GENE score (≥10). We hypothesize that ticagrelor is associated with better pharmacodynamic effects (i.e., lower platelet reactivity and high platelet reactivity rates) compared with clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention with a high ABCD-GENE score.
Trial Details
NCT Number NCT06228456
Lead Sponsor University of Florida
Collaborators: Scott R. MacKenzie Foundation
Conditions Coronary Artery Disease
Enrollment 50 participants
Start Date 2024-04-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-05